Spyre Therapeutics, Inc. (SYRE) stock analysis
In our weekly check, Spyre Therapeutics, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 7 pass, warnings: 2, red flags: 13.
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as SYRE.
What our checks show for SYRE
Red flags
- The gross margin fell by 50 points, to 50%: costs are rising faster than prices.
- Weak EPS forecast
- Analysts expect revenue to shrink about 93.4% a year.
- Analysts expect the net margin to shrink by 141033 points from today's -292%.
- Earnings per share fell 52.1% a year over the last 3 years.
- The company is losing money: the net margin is -292%.
- Free cash flow is negative (-276% of revenue): the business spends more cash than it brings in.
- The price swings a lot: 64.4% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 99% from a peak. Would you have held through that?
- Beta 3.23: the stock usually moves more than the market, both up and down.
- The share count grew by 829% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- The stock is still below its previous peak.
Strengths
- Debt is low: 0x equity.
- The company has no debt, so interest is not a risk.
- The net margin rose by 59.6 points over 5 years, to -292%.
- Revenue grew 239% a year over the last 3 years.
Similar companies
MDGL · TGTX · PCVX · PRAX · KRYS · KYMR
Questions
What grade does Spyre Therapeutics, Inc. (SYRE) have?
In our weekly check, Spyre Therapeutics, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 7 pass, warnings: 2, red flags: 13. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of SYRE stock?
This week's biggest flags for Spyre Therapeutics, Inc.: Gross margin falling, Weak EPS forecast, Weak revenue forecast. In total 15 of 22 checks show a warning or a red flag.
What does Spyre Therapeutics, Inc. do?
Spyre Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as SYRE.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis